

APR 14 1983

Stephen Kurzman, P.C.
Nixon, Hargrave, Devans and Doyle
1090 Vermont Avenue, N.W. (Suite 1200)
Washington, DC 20005

Re: Docket No. 81N-0022/CP0002 and
Docket No. 76N-052N/CP0003

Dear Mr. Kurzman:

This is in reply to the citizen petitions submitted to the Food and Drug Administration on January 11, 1983 and February 18, 1983, requesting that the administrative record for the OTC weight control drug products and the OTC nasal decongestant drug products rulemakings, respectively, be reopened to include new data and information on phenylpropanolamine hydrochloride.

The agency has decided to include the data in question in the administrative records for the rulemakings for OTC weight control drug products and OTC nasal decongestant drug products. In the advance notice of proposed rulemaking for OTC weight control drug products, published in the FEDERAL REGISTER of February 26, 1982 (47 FR 8466), the agency stated that it would continue to monitor further studies and information on phenylpropanolamine. The information accompanying your petition provides additional data regarding the safety of phenylpropanolamine hydrochloride. These data are currently being reviewed in conjunction with the development of the tentative final monographs (TFM) for OTC weight control drug products and OTC nasal decongestant drug products. The agency considers your petitions to be "feedback" communications.

In the FEDERAL REGISTER of September 29, 1981 (46 FR 47740), announcing the "feedback" policy, the agency stated that "feedback" communications would not be included in the administrative record for the related OTC monograph unless the communication directly influences an agency decision on a particular matter in the monograph or provides the substantiation for the agency's decision on that matter. We also stated that the results of a study would be included when they were one of the bases for the Commissioner's decision on an ingredient. This feedback policy was further clarified in the FEDERAL REGISTER of April 1, 1983 (48 FR 14050). Because the studies accompanying your petition will be used by the agency in reaching a decision on the classification of phenylpropanolamine hydrochloride in the respective TFMs, the agency is including them in the appropriate administrative records at this time.

76N-052N

PAV001


Stephen Kurzman, P.C.

Page 2

Should you have any questions regarding this matter, please refer to the appropriate Docket Numbers above and submit the inquiry in triplicate to the:

Dockets Management Branch
Food and Drug Administration
Room 4-62
5600 Fishers Lane
Rockville, MD 20857

Sincerely yours,


William F. Randolph
Acting Associate Commissioner
for Regulatory Affairs

cc: HF-1
HF-2
HF-43
GCF-1 (2)
HFA-224
HFA-30 (Docket No. 81N-0022) and (Docket No. 78N-052N)
HFC-1
HFC-2
HFC-10
HFN-1
HFN-7
HFN-200
HFN-500
HFN-510: ING 40.33/DDC 980.3/DDC 370.3/Reading/Rachanow
HFN-513: Reading/Bader/Cothran
HFN-514: Reading/Myers/Short
RD: JShort/2/18/83/lj/2/18/83
RE-RD: JShort/2/25/83/lj/2/28/83
END: GRachanow/3/7/83
END: WGilbertson/3/7/83
END: GKnapp/3/10/83
END: MWatson/3/15/83
END: JHalperin/3/28/83
END: BRice/4/6/83
END: KBaumgartner/4/11/83
FINAL: ljones/4/12/83
DOC ID 5566C/DISKETTE 079C

D. Jones 4/12/83

G.R. 4/12/83